Evaluating Beta-Blocker Discontinuation Post-Myocardial Infarction

Created using ChatSlide

The study titled "Beta-Blocker Discontinuation" by Choi et al., published in NEJM in March 2026, investigates the disputed role of beta-blockers post-myocardial infarction, especially in patients with preserved left ventricular ejection fraction. Conducted as an open-label, randomised trial across 25 centres in South Korea, the primary endpoint was composite cardiovascular events. The results showed a 7.2% versus 9.0% event rate, with a hazard ratio of 0.80, confirming noninferiority of...